Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study
Arthritis & Rheumatology · 2024-08 · 76 (8) · 1278-1287
DOI: 10.1002/art.42852 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 30.04.2024. Verfasst von Xenofon Baraliakos und 17 weiteren Autor:innen. Beteiligte Einrichtung: Ruhr-University, Herne, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Disease Progression, Adalimumab, Antirheumatic Agents. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.
Abstract (Originalsprache)
Objective
Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin‐17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ‐ADL]; tumor necrosis factor inhibitor).
Methods
Biologic‐naive patients with active radiographic axial SpA, at high risk of radiographic progression (high‐sensitivity C‐reactive protein [hsCRP] ≥5 mg/L and/or ≥1 syndesmophyte[s] on spinal radiographs), were randomized (1:1:1) to secukinumab (150/300 mg) or SDZ‐ADL (40 mg). The proportion of patients with no radiographic progression (change from baseline [CFB] in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤0.5) on secukinumab versus SDZ‐ADL at week 104 (primary endpoint), mean CFB‐mSASSS, proportion of patients with ≥1 syndesmophyte(s) at baseline with no new syndesmophyte(s), and safety were evaluated.
Results
Overall, 859 patients (78.5% male, mSASSS 16.6, Bath Ankylosing Spondylitis Disease Activity Index 7.1, hsCRP 20.4 mg/L, and 73.0% with ≥1 syndesmophyte[s]) received secukinumab 150 mg (n = 287), secukinumab 300 mg (n = 286), or SDZ‐ADL (n = 286). At week 104, the proportion of patients with no radiographic progression was 66.1%, 66.9%, and 65.6% ( P = not significant, both secukinumab doses) and mean CFB‐mSASSS was 0.54, 0.55, and 0.72 in secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL arms, respectively. Overall, 56.9%, 53.8%, and 53.3% of patients on secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL, respectively, with ≥1 syndesmophyte(s) at baseline did not develop new syndesmophyte(s) by week 104. There were no unexpected safety findings.
Conclusion
Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ‐ADL arms. The safety of both treatments was consistent with previous reports.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ruhr-University, Herne, Germany.
- Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark.
- Charité Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany.
- Leiden University Medical Center, Leiden, The Netherlands.
- Oregon Health & Science University, Portland.
- University College London, London, United Kingdom.
ORCID-Profile: Xenofon Baraliakos, Denis Poddubnyy, Atul Deodhar, Pedro M Machado, Kay Geert A Hermann, Mitsumasa Kishimoto, Eun Young Lee, Lianne S Gensler, Uta Kiltz
Förderung
- Novartis Pharma AG
Zitieren
APA
Baraliakos, X., Østergaard, M., Poddubnyy, D., van der Heijde, D., Deodhar, A., Machado, P. M., Navarro-Compán, V., Hermann, K. G. A., Kishimoto, M., Lee, E. Y., Gensler, L. S., Kiltz, U., Eigenmann, M. F., Pertel, P., Readie, A., Richards, H. B., Porter, B., & Braun, J. (2024). Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study. Arthritis & Rheumatology, 76(8), 1278-1287. https://doi.org/10.1002/art.42852
Vancouver
Baraliakos X, Østergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, et al. Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study. Arthritis & Rheumatology. 2024;76(8):1278-1287. doi:10.1002/art.42852
BibTeX
@article{Baraliakos2024,
author = {Baraliakos, Xenofon and Østergaard, Mikkel and Poddubnyy, Denis and van der Heijde, Désirée and Deodhar, Atul and Machado, Pedro M and Navarro-Compán, Victoria and Hermann, Kay Geert A and Kishimoto, Mitsumasa and Lee, Eun Young and Gensler, Lianne S and Kiltz, Uta and Eigenmann, Marco F and Pertel, Patricia and Readie, Aimee and Richards, Hanno B and Porter, Brian and Braun, Juergen},
title = {Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study},
journal = {Arthritis & Rheumatology},
year = {2024},
volume = {76},
number = {8},
pages = {1278--1287},
doi = {10.1002/art.42852}
}
EUVIMED